- Home
- BGLC vs ATNF Comparison
BGLC vs ATNF Comparison
Compare BGLC & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- ATNF
- Stock Information
- Founded
- BGLC 2017
- ATNF 2016
- Country
- BGLC Malaysia
- ATNF United States
- Employees
- BGLC N/A
- ATNF N/A
- Industry
- BGLC Medical Specialities
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- ATNF Health Care
- Exchange
- BGLC Nasdaq
- ATNF Nasdaq
- Market Cap
- BGLC 5.0M
- ATNF 5.0M
- IPO Year
- BGLC N/A
- ATNF N/A
- Fundamental
- Price
- BGLC $6.41
- ATNF $0.88
- Analyst Decision
- BGLC
- ATNF
- Analyst Count
- BGLC 0
- ATNF 0
- Target Price
- BGLC N/A
- ATNF N/A
- AVG Volume (30 Days)
- BGLC 2.7M
- ATNF 40.3K
- Earning Date
- BGLC 08-13-2025
- ATNF 08-11-2025
- Dividend Yield
- BGLC N/A
- ATNF N/A
- EPS Growth
- BGLC N/A
- ATNF N/A
- EPS
- BGLC N/A
- ATNF N/A
- Revenue
- BGLC $9,265,870.00
- ATNF N/A
- Revenue This Year
- BGLC N/A
- ATNF N/A
- Revenue Next Year
- BGLC N/A
- ATNF N/A
- P/E Ratio
- BGLC N/A
- ATNF N/A
- Revenue Growth
- BGLC N/A
- ATNF N/A
- 52 Week Low
- BGLC $2.01
- ATNF $0.66
- 52 Week High
- BGLC $15.60
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- BGLC 60.18
- ATNF 42.06
- Support Level
- BGLC $5.56
- ATNF $0.95
- Resistance Level
- BGLC $15.60
- ATNF $0.96
- Average True Range (ATR)
- BGLC 0.96
- ATNF 0.07
- MACD
- BGLC 0.52
- ATNF 0.00
- Stochastic Oscillator
- BGLC 29.46
- ATNF 27.73
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.